CalciMedica, Inc. CALC 深 滬
等待開盤 12-25 09:30:00 美东时间
6.21
+0.080
+1.31%
華盛通- 最 高6.30
- 今 開6.06
- 成交量 1.75万股
- 最 低 6.03
- 昨 收 6.13
- 總市值 8948.24万
- 52周最高 6.40
- 市盈率 靜 --
- 換手率 0.12%
- 52周最低 1.42
- 委 比 90.80%
- 總股本 1440.94万
- 歷史最高 8.59
- 量 比 0.17
- 振 幅 4.40%
- 歷史最低 1.42
- 每 手 1
- 風險率 0.91%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多CalciMedica Q3 EPS $(0.52) Misses $(0.42) Estimate
CalciMedica (NASDAQ:CALC) reported quarterly losses of $(0.52) per share which missed the analyst consensus estimate of $(0.42) by 22.93 percent. This is a 4 percent decrease over losses of $(0.50) per share from the
11-12 20:03
NOBLE CORPORATION PLC ANNOUNCES THIRD QUARTER 2025 RESULTS
Approximately $740 million in new contract value since August fleet status report, backlog increased to $7.0 billion. $0.50 per share cash dividend declared for Q4, bringing 2025 total share...
10-28 04:05
CalciMedica shares are trading lower after the company reported worse-than-expected Q2 EPS results.
CalciMedica shares are trading lower after the company reported worse-than-expe...
08-12 23:07
CalciMedica Q2 EPS $(0.40) Misses $(0.35) Estimate
CalciMedica (NASDAQ:CALC) reported quarterly losses of $(0.40) per share which missed the analyst consensus estimate of $(0.35) by 14.29 percent. This is a 11.11 percent decrease over losses of $(0.36) per share from the
08-12 19:08
CalciMedica Stockholders Approve Equity Plan Amendment
An update from CalciMedica ( ($CALC) ) is now available. On June 24, 2025, Calc...
06-28 04:46
CalciMedica Publishes Design And Rationale Of Phase 2 KOURAGE Trial Of Auxora In Acute Kidney Injury With Respiratory Failure, In American Journal Of Nephrology
Publication includes previously announced preclinical data of Auxora™ in acute kidney injury (AKI) models as well as a post-hoc analysis of patients in the Phase 2 CARDEA trial of Auxora in severe COVID-19
06-25 19:03
BioLineRx Reports First Quarter 2025 Financial Results and Provides Corporate Update
- Reports continued progress in the evaluation of assets for potential in-licensing and development in the areas of oncology and rare disease - - New data from pilot phase of ongoing CheMo4M...
05-27 19:00
美股大行评级 | 潜在涨幅1281.22%！Cabaletta Bio获Guggenheim升目标价至25美元，维持"买入"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1130057143861719040.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Guggenheim：维持Cabaletta Bio(CABA)"买入"评级，目标价从23美元升至25美元</p> <p>• 瑞穗：维持Tectonic Therapeutic(TECX)"跑赢大市"评级，目标价从51美元
05-16 08:43
HC Wainwright & Co. Reiterates Buy on CalciMedica, Maintains $16 Price Target
HC Wainwright & Co. analyst Joseph Pantginis reiterates CalciMedica (NASDAQ:CALC) with a Buy and maintains $16 price target.
05-15 19:13
CalciMedica Q1 EPS $(0.36) Misses $(0.31) Estimate
CalciMedica (NASDAQ:CALC) reported quarterly losses of $(0.36) per share which missed the analyst consensus estimate of $(0.31) by 16.13 percent. This is a 3700 percent decrease over earnings of $0.01 per share from the
05-14 19:09
